← Eichor
Study identifier: NCT05652569 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer  ·  Sponsor: German Cancer Research Center

PhaseN/A
Planned participants5000
Who can joinAll sexes, 14 Years to 100 Years
Healthy volunteersNo

About this study

CATCH is an indication-specific diagnostic platform, which drives the implementation of integrative, genomic profiling for metastatic breast cancer into the clinics. The main objective of this approach is to identify biomarkers and drug targets to guide targeted therapeutic interventions. Eligible are all metastatic breast cancer patients (independent of gender), irrespective of molecular subtype. At initial diagnosis of distant metastasis or progress at disease progression, biopsy samples from a prognostic-relevant metastasis are retrieved during standard-of-care procedures for central analyses, together with blood samples. In parallel to all standard-diagnostic measures, genomic and transcriptomic profiling is conducted to infer the underlying biology of the disease and identify patients who might profit from biomarker-guided interventions in clinical trials. Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data). In summary, the overarching goal is to generate a precision oncology platform to i) identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) couple the observational, diagnostic registry pla…

This description comes directly from the study's public registry record.

Talk to the study team

Andreas Schneeweiss, MD  ·  0049-6221-5636051  ·  Andreas.Schneeweiss@med.uni-heidelberg.de

Peter Lichter, PhD  ·  0049-6221-424609  ·  Peter.Lichter@Dkfz-Heidelberg.de

Always discuss trial participation with your own doctor first.

Locations (12)

University Hospital AugsburgAugsburg, GermanyRecruiting
CharitéBerlin, GermanyRecruiting
University Hospital KölnCologne, GermanyRecruiting
Medical Faculty and University Hospital Carl Gustav CarusDresden, GermanyRecruiting
University Hospital ErlangenErlangen, GermanyRecruiting
University Hospital EssenEssen, GermanyRecruiting
National Center for Tumor DiseasesHeidelberg, GermanyRecruiting
Caritas Hospital St. JosefRegensburg, GermanyRecruiting
Robert-Bosch-Krankenhaus StuttgartStuttgart, GermanyRecruiting
University Hospital TübingenTübingen, GermanyRecruiting
University Hospital UlmUlm, GermanyRecruiting
University Hospital WürzburgWürzburg, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05652569